Calderón Álvarez-Tostado JL, Bolaños-Jiménez R, Carrillo-Ruiz JD, Rivera-Silva G

Idioma: Español
Referencias bibliográficas: 41
Paginas: 218-225
Archivo PDF: 67.38 Kb.

RESUMEN

La enfermedad de Parkinson es uno de los más complejos e interesantes padecimientos del sistema nervioso central. Desde su descripción en 1817 por James Parkinson su causa sigue siendo un misterio, pero la investigación en esta área es intensa y los constantes hallazgos científicos ayudan a aclarar el panorama que la rodea. En la actualidad no existe tratamiento curativo de la enfermedad y sólo se cuenta terapias paliativas para mejorar los síntomas, por lo que es necesario comprender de manera más extensa las estructuras involucradas en su génesis y así elaborar estrategias que permitan encontrar cura a dicho padecimiento. En el presente escrito se presenta una revisión actualizada de las principales vías neuroanatómicas afectadas y su traducción clínica en síntomas motores y no motores.

REFERENCIAS (EN ESTE ARTÍCULO)

1. González-Torres LC, Armendáriz–Borunda J. Aspectos inmunológicos en la enfermedad de Parkinson. Arch Neurocien (Mex) 2005; 10: 168-9.

2. Jellinger KA. The Pathology of Parkinson’s disease. Adv Neurol 2001; 86: 55-72.

3. Forno LS. Neuropathology of Parkinson’s disease. J Neuropathol Exp Neurol 1996; 55: 259-72.

4. Gelb DG, Oliver E, Gilman S, Lees AJ. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-9.

5. Lees AJ. The Parkinson chimera. Neurology 2009; 72(Suppl. 2): S2- S11.

6. Braak H, Del Tredici K, Rub U, de Ros RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197-211.

7. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson’s disease. Neurology 2009; 72(Suppl. 4): S1- S136.

8. Djaldetti R, Ziv I, Melamed E. The mystery of motor asymmetry in Parkinson’s disease. Lancet Neurol 2006; 5: 796-802.

9. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993; 50: 140-8.

10. Kuhn AA, Williams D, Kupsch A, Limousin P, Hariz M, Schneider GH, et al. Event-related beta desynchronization in human subthalamic nucleus correlates with motor performance. Brain 2004; 127: 735-46.

11. Kuhn AA, Kupsch A, Schneider GH, Brown P. Reduction in subthalamic 8-35 Hz oscillatory activity correlates with clinical improvement in Parkinson’s disease. Eur J Neurosci 2006; 23: 1956-60.

12. Berardelli A, Rothwell JC, Thompson PD, Hallet M. Pathophysiology of bradykinesia in Parkinson’s disease. Brain 2001; 124: 2131-46.

13. Bagheri H, Damase-Michael C, Lapeyre-Mestre M, Cismondo S, O’Conell D, Senard JM, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol 1999; 67: 624-9.

14. Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006; 21: 1856-63.

15. Djaldetti R, Melamed E. Camptocormia in Parkinson’s disease: new insights. J Neurol Neurosurg Psychiatry 2006; 77: 1205.

16. Kunzle H. Bilateral projections from precentral motor cortex to the putamen and other parts of the basal ganglia. Brain Res 1975; 88: 195- 209.

17. Jones EG, Coulter JD, Burton H, Porter R. Cells of origin and terminal distribution of corticostriatal fibers arising in the sensory-motor cortex of monkeys. J Comp Neurol 1977; 173(1): 53-80.

18. De Long MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007; 64: 20-4.

19. Lee MS, Rinne JO, Marsden CD. The pedunculopontine nucleus: its role in the genesis of movement disorders. Yonsei Med J 2000; 41(2): 167-84.

20. Nicholson G, Pereira AC, Hall GM. Parkinson’s disease and anesthesia. Br J Anaesth 2002; 89: 904-16.

21. Lang AE, Lozano AM. Parkinson’s disease: second of two parts. N Engl J Med 1998; 339: 1130-43.

22. Hornykiewicz O. Chemical neuroanatomy of the basal ganglia — normal and in Parkinson’s disease. J Chem Neuroanat 2001; 22: 3-12.

23. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-75.

24. Bloem BR. Postural instability in Parkinson’s disease. Clin Neurol Neurosurg 1992; 94: S41-S45.

25. Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, et al. Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology 2001; 56: 1712-21.

26. Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson’s disease: a review of two interconnected, episodic phenomena. Mov Disord 2004; 19: 871-84.

27. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. TINS 1990; 13(7): 266-71.

28. Thomas RJ. Blinking and the release reflexes: are they clinically useful? J Am Geriatr Soc 1994; 42: 609-13.

29. Brodsky H, Dat Vuong K, Thomas M, Jankovic J. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology 2004; 63: 1096-8.

30. Hunker CJ, Abbs JH, Barlow SM. The relationship between parkinsonian rigidity and hypokinesia in the orofacial system: a quantitative analysis. Neurology 1982; 32: 749-54.

31. Zesiewicz TA, Sullivan KL, Hauser RA. Nonmotor symptoms of Parkinson’s disease. Exp Rev Neurother 2006; 6: 1811-22.

32. Biousse V, Skibell BC, Watts RL, Loupe DN, Drews-Botsch C, Newman NJ. Ophtalmologic features of Parkinson’s disease. Neurology 2004; 62: 177-80.

33. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al. Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated caregiver stress. J Neurol Neurosurg Psychiatry 2007; 78: 36-42.

34. Rascol O, Clanet M, Montastruc JL, Simonetta M, Soulier-Esteve MJ, Doyon B, et al. Abnormal ocular movements in Parkinson’s disease: evidence for involvement of dopaminergic systems. Brain 1989; 112: 1193-214.

35. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology 2001; 57: 1392-6.

36. Gagnon JF, Postuma BB, Mazza S, Doyon J, Montplaisir J. Rapid-eyemovement sleep behavior disorder and neurodegenerative diseases. Lancet Neurol 2006; 5: 424-32.

37. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 2007; 130: 1586-95.

38. Ishizaki F, Kito S. Definition and classification of neurotransmitters. Nippon Rinsho. 42, 779-784 (1984).

39. Amenta F, Zacchelo D, Collier WL. Neurotransmitters, neuroreceptors and aging. Mechanism of Ageing and Development 1991; 61: 249- 273.

40. Monographs in neural sciences. Vol. 10, neuroreceptors in health and disease. Marwaha J, Anderson WJ, Krager S (eds.). 1984. Trends in Pharmacological Sciences. Vol. 6. 1985, p. 138-9.

41. Usdin E, Bunney WEJr, Davis, Wiley SJ. Neuroreceptors: Basic and Clinical Aspects. Usdin E, Bunney WEJr, Davis, Wiley SJ (eds.). 1981. Trends in Neurosciences. Vol. 5. 1982, p. 251.